Last Updated: June 11, 2026

CLINICAL TRIALS PROFILE FOR DULAGLUTIDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Dulaglutide

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00630825 ↗	A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus	Completed	Eli Lilly and Company	Phase 2	2008-04-01	To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.
NCT00734474 ↗	A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin	Completed	Berry Consultants	Phase 2/Phase 3	2008-08-01	This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.
NCT00734474 ↗	A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin	Completed	Tessella Inc.	Phase 2/Phase 3	2008-08-01	This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.
NCT00734474 ↗	A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin	Completed	United BioSource Corporation	Phase 2/Phase 3	2008-08-01	This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.
NCT00734474 ↗	A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin	Completed	United BioSource, LLC	Phase 2/Phase 3	2008-08-01	This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.
NCT00734474 ↗	A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin	Completed	Eli Lilly and Company	Phase 2/Phase 3	2008-08-01	This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Dulaglutide

Condition Name

Chart
Table

Condition Name for Dulaglutide
Intervention	Trials
Diabetes Mellitus, Type 2	33
Type 2 Diabetes	20
Type 2 Diabetes Mellitus	15
Obesity	5
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Dulaglutide
Intervention	Trials
Diabetes Mellitus, Type 2	75
Diabetes Mellitus	64
Obesity	6
Fatty Liver	4
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Dulaglutide

Trials by Country

Map
Table

Trials by Country for Dulaglutide
Location	Trials
United States	509
China	59
Canada	42
India	41
Germany	40
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Dulaglutide
Location	Trials
Florida	30
Texas	30
California	28
North Carolina	19
New York	18
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Dulaglutide

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Dulaglutide
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	4
PHASE2	3
[disabled in preview]	48
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Dulaglutide
Clinical Trial Phase	Trials
Completed	50
Recruiting	18
Not yet recruiting	14
[disabled in preview]	13
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dulaglutide

Sponsor Name

Chart
Table

Sponsor Name for Dulaglutide
Sponsor	Trials
Eli Lilly and Company	52
University Hospital, Basel, Switzerland	4
Innovent Biologics (Suzhou) Co. Ltd.	3
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Dulaglutide
Sponsor	Trials
Industry	71
Other	45
NIH	3
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.